Targeting the Affluent: Differential Access to Targeted Therapies in China

Conquering Complexity, at a Price. This paper will illustrate how disparities in income levels continue to drive far-reaching differences in the way poorer and richer Chinese with cancer are being treated for their disease.

The author(s)

  • Pieter De Richter Ipsos Healthcare, Malaysia
Get in touch

The war against cancer is now being fought at a molecular level – harnessing the insights we have gained into the complexity of our enemy. However, this revolution is, quite literally, coming at a price. This new molecular battlefront isn’t just complex; it is incredibly hungry for money.

Different countries around the world have adopted the new tactics and tools at varying speeds and with markedly different levels of success. In particular, there is substantial variability between different countries’ ability to ensure equal access to the most effective – and often the most expensive – drug treatments for all citizens diagnosed with cancer.

Using data from the Ipsos Global Oncology Monitor ©, Pieter De Richter – Head of Real World Evidence in APAC and MENA – looks in-depth at China, exploring the differential access to anti-cancer therapies in this key Asian market.

The author(s)

  • Pieter De Richter Ipsos Healthcare, Malaysia

More insights about Health

Society